GSA Capital Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$305K Sell
606
-183
-23% -$96.7K 0.02% 1381
2026
Q2
$424K Buy
+789
New +$404K 0.03% 1108
2025
Q4
– Sell
-1,739
Closed -$798K – 1922
2025
Q3
$798K Buy
+1,739
New +$649K 0.07% 550
2023
Q2
– Sell
-3,240
Closed -$785K – 1771
2023
Q1
$785K Buy
+3,240
New +$883K 0.08% 451
2022
Q1
– Sell
-4,780
Closed -$405K – 1652
2021
Q4
$405K Sell
4,780
-4,376
-48% -$360K 0.05% 737
2021
Q3
$731K Buy
9,156
+4,153
+83% +$359K 0.07% 468
2021
Q2
$487K Buy
+5,003
New +$592K 0.05% 645
2021
Q1
– Sell
-3,334
Closed -$371K – 1324
2020
Q4
$371K Buy
+3,334
New +$408K 0.06% 628
2020
Q1
– Sell
-12,241
Closed -$1.12M – 1350
2019
Q4
$1.12M Buy
12,241
+8,564
+233% +$831K 0.13% 161
2019
Q3
$317K Buy
+3,677
New +$345K 0.04% 854
2018
Q3
– Sell
-1,702
Closed -$476K – 1783
2018
Q2
$476K Buy
+1,702
New +$299K 0.02% 1183
2015
Q2
– Sell
-894
Closed -$61K – 2090
2015
Q1
$61K Buy
+894
New +$76.7K ﹤0.01% 2047

Other funds holding MDGL

GSA Capital Partners's MDGL Position: Q3 2026 in Review

GSA Capital Partners reduced its Madrigal Pharmaceuticals (MDGL) stake by 23% in Q3 2026, selling an estimated $96.7K and leaving 606 shares worth $305K. The position accounts for 0.02% of the portfolio, ranked #1381.

GSA Capital Partners first reported a position in MDGL in Q1 2015 and has held it in 12 quarters since. The position peaked at $1.12M in Q4 2019. 437 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

  • GSA Capital Partners held 606 shares of Madrigal Pharmaceuticals worth $305K as of Q3 2026.
  • GSA Capital Partners sold 183 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $96.7K.
  • Madrigal Pharmaceuticals made up 0.02% of GSA Capital Partners's portfolio in Q3 2026, its #1381 holding.
  • GSA Capital Partners first reported a position in Madrigal Pharmaceuticals in Q1 2015 and has held it in 12 quarters since.
  • GSA Capital Partners's Madrigal Pharmaceuticals position peaked at $1.12M in Q4 2019.
  • 437 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.